Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
The purpose on this study was to determine whether the test product, Haloperidol Tablets, 2
mg (Cycle Pharmaceuticals Ltd), and the reference product, Haloperidol Tablets, USP, 2 mg
(Mylan Pharmaceuticals Inc.) are bioequivalent under fed conditions.